Annex 1

Data collecting form for all patients on clozapine:

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Patient code | Age | Gender | Diagnosis | Clozapine dose (mg) | Treatment schedule (1 monotherapy; 2-politherapy) | Other antipsychotics with dosing |
|  |  |  |  |  |  |  |

Form for patients on clozapine and cariprazine combination:

|  |  |
| --- | --- |
| Case number |  |
| Illness duration (in years) |  |
| Number of previous ineffective pharmacotherapy trials prior to the use of clozapine + cariprazine combination |  |
| Antipsychotic used in combination with clozapine prior to switch to cariprazine |  |
| Somatic comorbidities |  |
| Addictions |  |
| Other psychotropic medications used at the time of adding the antipsychotic |  |
| Nonpsychiatric medications (with daily doses) |  |
| Initial dose of cariprazine |  |
| Target dose of cariprazine |  |
| Duration of the combined treatment (clozapine + cariprazine), in months |  |
| Clozapine dose (mg) |  |
| **Symptoms at the beginning of the combined clozapine + cariprazine treatment:** | |
| Residual positive symptoms (1-yes; 0-no) |  |
| Exacerbation of positive symptoms (1-yes; 0-no) |  |
| Negative symptoms (1-yes; 0-no) |  |
| Depressive symptoms (1-yes; 0-no) |  |
| Anxiety (1-yes; 0-no) |  |
| Suicidal thoughts (1-yes; 0-no) |  |
| Cognitive dysfunctions (1-yes; 0-no) |  |
| Sexual dysfunctions (1-yes; 0-no) |  |
| Hyperprolactinemia (1-yes; 0-no) |  |
| Overweight/Obesity (1-yes; 0-no) |  |
| Disorders of glucose metabolism (1-yes; 0-no) |  |